Hypertrophic Cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Hypertrophic cardiomyopathy (HCM) is a genetic heart condition often inherited in an autosomal-dominant pattern.
• Early diagnosis and management are essential for affected individuals and their families.

Purpose of the Study:

• To outline the diagnostic and therapeutic strategies for hypertrophic cardiomyopathy (HCM).
• To emphasize risk stratification for sudden cardiac death and thromboembolic events.

Main Methods:

• Family screening with electrocardiogram (ECG) and echocardiogram for potential Mendelian autosomal-dominant inheritance.
• Consideration of genetic testing for high-risk mutations with diagnostic uncertainties.
• Pharmacological interventions including beta-blockers, calcium channel blockers, and disopyramide.
• Non-pharmacological treatments such as surgical myectomy, alcohol septal ablation, and dual-chamber pacing.
• Close monitoring for atrial fibrillation (AF) and thromboembolic risk, with a low threshold for anticoagulation.

Main Results:

• Beta-blockers are first-line therapy for symptom relief.
• Disopyramide is effective for obstructive HCM, ideally with beta-blockers.
• Surgical myectomy is the gold standard, while septal ablation offers good results in experienced hands.
• Atrial fibrillation and left atrial enlargement increase thromboembolic risk.
• Key predictors of sudden cardiac death include prior cardiac arrest, syncope, family history, exercise BP response, VT, and severe LVH.

Conclusions:

• Comprehensive evaluation including family screening, genetic testing, and risk stratification is vital for HCM management.
• Pharmacological and non-pharmacological therapies should be individualized based on disease phenotype and patient risk.
• Vigilant monitoring for arrhythmias and thromboembolic events, with prompt anticoagulation when indicated, is critical.